At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Trading 04-20 13:25:07 EDT
1.14
+0.42
+58.57%
High1.52Low1.05Vol203.01M
Open1.33D1 Closing0.7196Amplitude65.31%
Mkt Cap2.38MTradable Cap2.31MTotal Shares2.09M
T/O260.05MT/O Rate10,040.65%Tradable Shares2.02M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Reuters  ·  04-20 21:34
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial
Reuters  ·  04-20 19:15
Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial
Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events
THOMSON REUTERS  ·  04-20 19:15
Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
GlobeNewswire  ·  04-20 19:15
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
TIPRANKS  ·  04-16
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
Clearmind announces DSMB recommendation to continue CMND-100 trial
TIPRANKS  ·  04-16
Clearmind announces DSMB recommendation to continue CMND-100 trial
Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg
Reuters  ·  04-15
Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg
Clearmind Medicine Inc - Cmnd-100 Well Tolerated With No Serious Adverse Events in Third Cohort
THOMSON REUTERS  ·  04-15
Clearmind Medicine Inc - Cmnd-100 Well Tolerated With No Serious Adverse Events in Third Cohort
Clearmind Medicine Inc - to Proceed to Fourth Cohort, Increase Cmnd-100 Dose to 160Mg
THOMSON REUTERS  ·  04-15
Clearmind Medicine Inc - to Proceed to Fourth Cohort, Increase Cmnd-100 Dose to 160Mg
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing Cmnd-100 Clinical Trial
THOMSON REUTERS  ·  04-15
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing Cmnd-100 Clinical Trial
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
GlobeNewswire  ·  04-15
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
Clearmind Medicine issues $1.75 million convertible notes, raises $1.58 million cash
Reuters  ·  04-15
Clearmind Medicine issues $1.75 million convertible notes, raises $1.58 million cash
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere
Reuters  ·  04-14
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere
BUZZ-Clearmind Medicine rises after alcohol addiction drug shows safety in early trial
Reuters  ·  04-14
BUZZ-Clearmind Medicine rises after alcohol addiction drug shows safety in early trial
Clearmind Medicine Inc - Third Cohort Results Show High Safety Profile for Cmnd-100 With No Serious Adverse Events
THOMSON REUTERS  ·  04-14
Clearmind Medicine Inc - Third Cohort Results Show High Safety Profile for Cmnd-100 With No Serious Adverse Events
Clearmind Medicine Inc - Phase I/Iia Trial Evaluates Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Cmnd-100
THOMSON REUTERS  ·  04-14
Clearmind Medicine Inc - Phase I/Iia Trial Evaluates Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Cmnd-100
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
GlobeNewswire  ·  04-14
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
TIPRANKS  ·  04-02
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
GlobeNewswire  ·  03-30
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders
Reuters  ·  03-27
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--